Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of sacituzumab govitecan versus topotecan in previously treated extensive-stage small cell lung cancer
MOH_2025-05-26_014113Phase 3Not yet recruiting
- Sponsor
- Gilead Sciences
- Start
- May 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of sacituzumab govitecan in small cell lung cancer (SCLC) (2 arms), sponsored by Gilead Sciences. Primary endpoint: Objective response rate. Planned start May 2025; status: not yet recruiting.
02
Drugs
sacituzumab govitecan
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on MOH_2025-05-26_014113.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2025-05-26_014113.